Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients

Raffaella Fontana, Marco Bregni, Arcadi Cipponi, Laura Raccosta, Cristina Rainelli, Daniela Maggioni, Francesca Lunghi, Fabio Ciceri, Sylvain Mukenge, Claudio Doglioni, Didier Colau, Pierre G. Coulie, Claudio Bordignon, Catia Traversari, Vincenzo Russo

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)- based immunity in tumor murine models. Our group has recently demonstrated in preclinical models that the infusion of genetically modified lymphocytes (GMLs) expressing the self/tumor antigen TRP-2 is able to elicit functional TRP-2-specific effectors with antitumor activity by targeting DCs in vivo. Here we have analyzed vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti- MAGE-A3 T cells, and developed skin de-layed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors. Clinical studies on a larger group of patients are needed to evaluate the clinical efficacy of such a strategy.

Original languageEnglish
Pages (from-to)1651-1660
Number of pages10
JournalBlood
Volume113
Issue number8
DOIs
Publication statusPublished - Feb 19 2009

Fingerprint

T-cells
Lymphocytes
Autoantigens
Neoplasm Antigens
Tumors
Blood
T-Lymphocytes
Neoplasms
Cancer Vaccines
Neoplasm Genes
Cytotoxic T-Lymphocytes
Dendritic Cells
Immunity
Melanoma
Skin
Hypersensitivity
Vaccination
Genes
Tissue

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. / Fontana, Raffaella; Bregni, Marco; Cipponi, Arcadi; Raccosta, Laura; Rainelli, Cristina; Maggioni, Daniela; Lunghi, Francesca; Ciceri, Fabio; Mukenge, Sylvain; Doglioni, Claudio; Colau, Didier; Coulie, Pierre G.; Bordignon, Claudio; Traversari, Catia; Russo, Vincenzo.

In: Blood, Vol. 113, No. 8, 19.02.2009, p. 1651-1660.

Research output: Contribution to journalArticle

Fontana, R, Bregni, M, Cipponi, A, Raccosta, L, Rainelli, C, Maggioni, D, Lunghi, F, Ciceri, F, Mukenge, S, Doglioni, C, Colau, D, Coulie, PG, Bordignon, C, Traversari, C & Russo, V 2009, 'Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients', Blood, vol. 113, no. 8, pp. 1651-1660. https://doi.org/10.1182/blood-2008-07-168666
Fontana, Raffaella ; Bregni, Marco ; Cipponi, Arcadi ; Raccosta, Laura ; Rainelli, Cristina ; Maggioni, Daniela ; Lunghi, Francesca ; Ciceri, Fabio ; Mukenge, Sylvain ; Doglioni, Claudio ; Colau, Didier ; Coulie, Pierre G. ; Bordignon, Claudio ; Traversari, Catia ; Russo, Vincenzo. / Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. In: Blood. 2009 ; Vol. 113, No. 8. pp. 1651-1660.
@article{9b9dce493a084249a457b5e882a068e7,
title = "Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients",
abstract = "Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)- based immunity in tumor murine models. Our group has recently demonstrated in preclinical models that the infusion of genetically modified lymphocytes (GMLs) expressing the self/tumor antigen TRP-2 is able to elicit functional TRP-2-specific effectors with antitumor activity by targeting DCs in vivo. Here we have analyzed vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti- MAGE-A3 T cells, and developed skin de-layed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors. Clinical studies on a larger group of patients are needed to evaluate the clinical efficacy of such a strategy.",
author = "Raffaella Fontana and Marco Bregni and Arcadi Cipponi and Laura Raccosta and Cristina Rainelli and Daniela Maggioni and Francesca Lunghi and Fabio Ciceri and Sylvain Mukenge and Claudio Doglioni and Didier Colau and Coulie, {Pierre G.} and Claudio Bordignon and Catia Traversari and Vincenzo Russo",
year = "2009",
month = "2",
day = "19",
doi = "10.1182/blood-2008-07-168666",
language = "English",
volume = "113",
pages = "1651--1660",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients

AU - Fontana, Raffaella

AU - Bregni, Marco

AU - Cipponi, Arcadi

AU - Raccosta, Laura

AU - Rainelli, Cristina

AU - Maggioni, Daniela

AU - Lunghi, Francesca

AU - Ciceri, Fabio

AU - Mukenge, Sylvain

AU - Doglioni, Claudio

AU - Colau, Didier

AU - Coulie, Pierre G.

AU - Bordignon, Claudio

AU - Traversari, Catia

AU - Russo, Vincenzo

PY - 2009/2/19

Y1 - 2009/2/19

N2 - Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)- based immunity in tumor murine models. Our group has recently demonstrated in preclinical models that the infusion of genetically modified lymphocytes (GMLs) expressing the self/tumor antigen TRP-2 is able to elicit functional TRP-2-specific effectors with antitumor activity by targeting DCs in vivo. Here we have analyzed vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti- MAGE-A3 T cells, and developed skin de-layed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors. Clinical studies on a larger group of patients are needed to evaluate the clinical efficacy of such a strategy.

AB - Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)- based immunity in tumor murine models. Our group has recently demonstrated in preclinical models that the infusion of genetically modified lymphocytes (GMLs) expressing the self/tumor antigen TRP-2 is able to elicit functional TRP-2-specific effectors with antitumor activity by targeting DCs in vivo. Here we have analyzed vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti- MAGE-A3 T cells, and developed skin de-layed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors. Clinical studies on a larger group of patients are needed to evaluate the clinical efficacy of such a strategy.

UR - http://www.scopus.com/inward/record.url?scp=61949105112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61949105112&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-07-168666

DO - 10.1182/blood-2008-07-168666

M3 - Article

VL - 113

SP - 1651

EP - 1660

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -